Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Apellis Pharmaceuticals IncAPLS-5.3411.8612.13-12.02-109.19%-52.90%67.78$29.47$88.37110,378$26.90

Detail of Apellis Pharmaceuticals Inc

 
CEO
Dr. Cedric Francois M.D., Ph.D.
Employees
476
Industry
Biotechnology
Sector
Healthcare
Market cap
$3B

Company details

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$272.88M
Cost of goods (CoG)
-$41.52M
Gross profit (GP)
$231.35M
Operating expense (OE)
-$828.01M
Research and development (R&D)
-$384.53M
General and administrative (G&A)
-$443.48M
Operating income (OI)
-$596.66M
Other income expense (OIE)
-$1.19M
Pretax income (PI)
-$606.80M
Tax (TAX)
$762,000.00
Net income (NI)
-$606.04M
Apellis Pharmaceuticals Inc
APLS • XNGS • US
$26.90
-17.50 (-39.41%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$5.04
Margin profit
-52.94%
52 week low
$26.545
52 week high
$72.470001
50-day simple moving average
$28.47
200-day simple moving average
$29.47
Percent held by insiders
14.28%
Percent held by institutions
97.34%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
APLS -40.12%
eps change
APLS 0.00%